The evolving role of taurolidine in cancer therapy

Annals of Surgical Oncology

Volumn 17, Issue 4, 2010, Pages 1135-1143

  Neary, Peter M ^a   Hallihan, Patrick ^a   Wang, Jiang H ^a   Pfirrmann, Rolf W ^b   Bouchier Hayes, David J ^c   Redmond, Henry P ^a  

^a Department of Medicine National University of Ireland Cork   (Ireland)

^b Beaumont Hospital ^*

^c BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C; CYTOKINE; TAUROLIDINE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER INHIBITION; CYTOKINE RELEASE; DRUG MECHANISM; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; TAURINE; THIADIAZINES;

EID: 77952094869     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0867-9     Document Type: Review

References (79)

1. B Knight G Skellern G Smail M Browne R Pfirrmann 1983 NMR studies and GC analysis of the antibacterial agent taurolidine J Pharmaceut Sci 72 705 7 10.1002/jps.2600720630 1:CAS:528:DyaL3sXksVelsbk%3D (Pubitemid 13062806)
2. R Pfirrmann 1991 Taurolin in der Anwendung bei chirurgischen Infektionen Chir Gastroenterol. 6 131 142
3. Pfirrmann R, Bruckner W. Taurolin-Ein neues Konzept zur antimikrobiellen Chemotherapie chirurgischer Infektionen. Munich: Urban and Schwarzenberg; 1985. p. 3-23.
4. ®) in adhesion prevention: An experimental study on mice Dis Colon Rectum. 50 2209 2214 10.1007/s10350-007-9074-6 17902020 (Pubitemid 350275872)
5. H Reith 1997 Therapy of peritonitis today. Surgical management and adjuvant therapy strategies Langenbecks Arch Chir. 382 S14 10.1007/PL00014637 1:STN:280:DyaK2svhtFGhtw%3D%3D 9333701 (Pubitemid 28006195)
6. J Luo H Kamata M Karin 2005 IKK/NF-B signaling: Balancing life and death-a new approach to cancer therapy Am Soc Clin Invest. 115 2625 2632 10.1172/JCI26322 1:CAS:528:DC%2BD2MXhtVygt7vE (Pubitemid 41434385)
7. J Marshall D Foster J Vincent, et al. 2004 Diagnostic and prognostic implications of endotoxemia in critical illness: Results of the MEDIC study J Infect Dis. 190 527 534 10.1086/422254 1:CAS:528:DC%2BD2cXmvF2ntrc%3D 15243928 (Pubitemid 38982092)
8. D Scevola G Barbarini P Marone M Azzini C Filice R Bernardi 1979 Anti-endotoxin therapy in liver diseases G Ital Chemioter 26 241 1:STN:280:DyaL3M7hsFahtA%3D%3D 400139
9. G Görtz 1997 Local antiseptic and anti-endotoxin measures in intra-abdominal infections Langenbecks Arch Chir. 382 S37 10.1007/PL00014642 9333706 (Pubitemid 28006200)
10. A Dofferhoff M Esselink H de Vries-Hospers, et al. 1993 The release of endotoxin from antibiotic-treated Escherichia coli and the production of tumour necrosis factor by human monocytes Br Soc Antimicrob Chemother. 31 373 384 10.1093/jac/31.3.373 1:CAS:528:DyaK3sXktVCrsL8%3D (Pubitemid 23110677)
11. W Traub B Leonhard D Bauer 1993 Taurolidine: In vitro activity against multiple-antibiotic-resistant, nosocomially significant clinical isolates of Staphylococcus aureus, Enterococcus faecium, and diverse Enterobacteriaceae Chemotherapy (Basel) 39 322 330 1:CAS:528:DyaK3sXltlGnsbk%3D (Pubitemid 23238716)
12. M McCourt J Wang S Sookhai H Redmond 2000 Taurolidine inhibits tumor cell growth in vitro and in vivo Ann Surg Oncol. 7 685 691 10.1007/s10434-000-0685-6 1:STN:280:DC%2BD3cvosFGrtQ%3D%3D 11034247
13. Linder M, Ott W, Wesch G. Antibacterial therapy of purulent peritonitis: A prospective randomized study on the effects of antibiotics and taurolin, a new chemotherapeutic and antiendotoxic agent (author's transl). Chir Forum Exp Klin Forsch. 1980:67-71. (Pubitemid 10088292)
14. M Browne 1981 The treatment of peritonitis by an antiseptic-taurolin Pharmatherapeutica. 2 517 1:STN:280:DyaL3M3kslKjsQ%3D%3D 7255507
15. B Jurewitsch T Lee J Park K Jeejeebhoy 1998 Taurolidine 2% as an antimicrobial lock solution for prevention of recurrent catheter-related bloodstream infections J Parenter Enteral Nutr. 22 242 10.1177/ 0148607198022004242 1:STN:280:DyaK1czisFGrsQ%3D%3D (Pubitemid 28307589)
16. Reith H, Dittrich H, Haarmann W, et al. Adjuvante Therapie der Peritonitis und ihren septischen Verlaufsformen mit Taurolidin-eine prospektive randomisierte Untersuchung. Chir Gastroenterol. 1996;12:358-62. (Pubitemid 27055348)
17. S Gorman D McCafferty A Woolfson D Jones 1987 Reduced adherence of micro-organisms to human mucosal epithelial cells following treatment with taurolin, a novel antimicrobial agent J Appl Microbiol. 62 315 320 10.1111/j.1365-2672.1987.tb04926.x 1:CAS:528:DyaL2sXksFWntLs%3D
18. J Blenkharn 1990 In-vitro antibacterial activity of noxythiolin and taurolidine J Pharm Pharmacol. 42 589 590 1:CAS:528:DyaK3MXjvFSqtA%3D%3D 1981591 (Pubitemid 20343446)
19. H Erpek P Tuncyurek A Soyder S Boylu 2006 Hyaluronic acid/ carboxymethylcellulose membrane barrier versus taurolidine for the prevention of adhesions to polypropylene mesh Eur Surg Res. 38 414 417 10.1159/000094748 1:CAS:528:DC%2BD28XptValurc%3D 16874004 (Pubitemid 44329064)
20. O Tarhan I Barut M Sezik 2008 An evaluation of normal saline and taurolidine on intra-abdominal adhesion formation and peritoneal fibrinolysis J Surg Res. 144 151 157 1:CAS:528:DC%2BD2sXhsVent7vP 17981298 (Pubitemid 350234967)
21. I Bedrosian R Sofia S Wolff C Dinarello 1991 Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells Cytokine. 3 568 10.1016/1043-4666(91)90483-T 1:CAS:528:DyaK38XhtVCisLc%3D 1790304
22. W Sendt E Mansouri A Schmitt-Graeff G Wolff-Vorbeck U Schoffel 2002 Influence of antiseptic agents on interleukin-8 release and transmigration of polymorphonuclear neutrophils in a human in vitro model of peritonitis Surg Infect. 3 235 244 10.1089/109629602761624199 (Pubitemid 36013615)
23. C Rosman G Westerveld K Kooi R Bleichrodt 1999 Local treatment of generalised peritonitis in rats; effects on bacteria, endotoxin and mortality Eur J Surg. 165 1072 1079 10.1080/110241599750007928 1:STN:280: DC%2BD3c%2FmtFSlsA%3D%3D 10595613 (Pubitemid 29529387)
24. C Rosman G Westerveld W Van Oeveren K Kooi R Bleichrodt 1996 Effect of intraperitoneal antimicrobials on the concentration of bacteria, endotoxin, and tumor necrosis factor in abdominal fluid and plasma in rats Eur Surg Res. 28 351 360 10.1159/000129476 1:CAS:528:DyaK28XlvF2rtrY%3D 8880124 (Pubitemid 26305848)
25. R Watson H Redmond J Mc Carthy D Bouchier-Hayes 1995 Taurolidine, an antilipopolysaccharide agent, has immunoregulatory properties that are mediated by the amino acid taurine Soc Leukocyte Biol. 58 299 306 1:CAS:528: DyaK2MXnvFeluro%3D
26. J Marcinkiewicz M Kurnyta R Biedron M Bobek E Kontny W Maslinski 2006 Anti-inflammatory effects of taurine derivatives (taurine chloramine, taurine bromamine, and taurolidine) are mediated by different mechanisms Adv Exp Med Biol. 583 481 10.1007/978-0-387-33504-9-54 1:CAS:528:DC%2BD1MXhtFWis7Y%3D 17153635
27. H Redmond A Leahy J Carey, et al. 1994 Beneficial effects of taurolidine in experimental pancreatitis J Surg Res. 56 256 260 10.1006/jsre.1994.1040 1:CAS:528:DyaK2cXksleis7s%3D 7511718 (Pubitemid 24100436)
28. A Chromik A Müller M Albrecht, et al. 2007 Oral administration of taurolidine ameliorates chronic DSS colitis in mice J Invest Surg 20 273 10.1080/08941930701598784 17972215 (Pubitemid 350048043)
29. J Marcinkiewicz P Głuszko E Kontny, et al. 2007 Is taurolidine a candidate for treatment of rheumatoid arthritis? Clin Exp Rheumatol 25 211 1:STN:280:DC%2BD2szjtF2guw%3D%3D 17543144 (Pubitemid 46860093)
30. C Jacobi R Sabat J Ordemann F Wenger H Volk J Müller 1997 Peritoneal instillation of taurolidine and heparin for preventing intraperitoneal tumor growth and trocar metastases in laparoscopic operations in the rat model Langenbecks Arch Chir. 382 S31 10.1007/PL00014641 1:STN:280:DyaK2svhtFGhuw%3D%3D 9333705 (Pubitemid 28006199)
31. C Jacobi F Peter F Wenger J Ordemann J Müller 1999 New therapeutic strategies to avoid intra-and extraperitoneal metastases during laparoscopy: Results of a tumor model in the rat Dig Surg. 16 393 399 10.1159/000018754 1:STN:280:DC%2BD3c%2Fjs12rug%3D%3D 10567800 (Pubitemid 29520956)
32. M Karin F Greten 2005 NF-B: linking inflammation and immunity to cancer development and progression Nat Rev Immunol. 5 749 759 10.1038/nri1703 1:CAS:528:DC%2BD2MXhtVGrurvL 16175180 (Pubitemid 41400849)
33. D Little M Regan D Bouchier-Hayes 1993 Perioperative immune modulation Surgery. 114 87 91 1:STN:280:DyaK3szmt1SrsA%3D%3D 8356532 (Pubitemid 23209347)
34. M Da Costa H Redmond D Bouchier-Hayes 2001 Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumors and development of organ metastases from circulating tumor cells released following surgery J Surg Res. 101 111 10.1006/jsre.2001.6250 1:CAS:528: DC%2BD3MXovFWisrY%3D 11735264 (Pubitemid 34044548)
35. B Böhm W Schwenk H Hucke W Stock 1993 Does methodic long-term follow-up affect survival after curative resection of colorectal carcinoma? Dis Colon Rectum. 36 280 286 10.1007/BF02053511 8449134 (Pubitemid 23077918)
36. J Darnowski F Goulette L Cousens D Chatterjee P Calabresi 2004 Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer Cancer Chemother Pharmacol. 54 249 258 10.1007/s00280-004-0806-1 1:CAS:528:DC%2BD2cXmt1KksLs%3D 15173956 (Pubitemid 39141742)
37. A Daigeler A Chromik A Geisler, et al. 2008 Synergistic apoptotic effects of taurolidine and TRAIL on squamous carcinoma cells of the esophagus Int J Oncol. 32 1205 10.3892/ijo-32-6-1205 1:CAS:528:DC%2BD1cXns1agu70%3D 18497982
38. F Wenger M Kilian C Braumann, et al. 2002 Effects of taurolidine and octreotide on port site and liver metastasis after laparoscopy in an animal model of pancreatic cancer Clin Exp Metastasis. 19 169 173 10.1023/A: 1014579718391 1:CAS:528:DC%2BD38XjtlCitLg%3D 11964081 (Pubitemid 34264087)
39. L Nici B Monfils P Calabresi 2004 The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma AACR. 10 7655 7661 1:CAS:528:DC%2BD2cXhtVanurzE (Pubitemid 39557529)
40. L Petrovic K Schlegel J Ries, et al. 2003 In vitro effect of taurolidine on squamous cell carcinoma in the oral cavity Mund Kiefer Gesichtschir. 7 102 1:STN:280:DC%2BD3s7ksl2gsg%3D%3D 12664255
41. R Stendel G Stoltenburg-Didinger C Al Keikh M Wattrodt M Brock 2002 The effect of taurolidine on brain tumor cells Anticancer Res. 22 809 1:CAS:528:DC%2BD38XktF2nu7w%3D 12014655 (Pubitemid 34475233)
42. D Walters R Muff B Langsam P Gruber W Born B Fuchs 2007 Taurolidine: A novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines Invest New Drugs. 25 305 312 10.1007/s10637-007-9052-9 1:CAS:528:DC%2BD2sXmsFKjtrc%3D 17458504 (Pubitemid 46944855)
43. A Daigeler C Brenzel D Bulut, et al. 2008 TRAIL and taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma J Exp Clin Cancer Res. 27 82 10.1186/1756-9966-27-82 19077262
44. B Sun J Wang L Liu S Gong H Redmond 2007 Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins J Surg Oncol. 96 241 248 10.1002/jso.20827 1:CAS:528:DC%2BD2sXhtFWhsrfF 17469118 (Pubitemid 350194623)
45. C Braumann C Menenakos V Atanassov R Pfirrmann N Guenther C Jacobi 2008 Leukopoiesis is not affected after intravenous treatment with the novel antineoplastic agent taurolidine results of an experimental study in rats Eur Surg Res. 40 341 346 10.1159/000118030 1:CAS:528:DC%2BD1cXmtVSmurw%3D 18303270 (Pubitemid 351704907)
46. R Stendel T Picht A Schilling, et al. 2004 Treatment of glioblastoma with intravenous taurolidine. First clinical experience Anticancer Res. 24 1143 1147 15154639 (Pubitemid 38624954)
47. G O'Brien R Cahill D Bouchier-Hayes 2006 Co-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma Irish J Med Sci. 175 10 14 10.1007/BF03168992 16615221
48. Braumann C, Winkler G, Rogalla P, Menenakos C, Jacobi C. Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case. World J Surg Oncol. 2006;4:34. (Pubitemid 44262718)
49. T Möhler M Willhauck-Fleckenstein R Schwartz-Albiez A Merling H Möhler 2008 Inhibition of endothelial cell adhesion and in vitro angiogenesis by Taurolidine Cancer Therapy. 6 623 628
50. R Rodak H Kubota H Ishihara, et al. 2005 Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine J Neurosurg. 102 1055 1068 10.3171/jns.2005.102.6.1055 1:CAS:528:DC%2BD2MXmtVShurs%3D 16028765 (Pubitemid 43193975)
51. Z Han I Ribbizi P Pantazis J Wyche J Darnowski P Calabresi 2002 The antibacterial drug taurolidine induces apoptosis by a mitochondrial cytochrome c-dependent mechanism Anticancer Res. 22 1959 1964 1:CAS:528: DC%2BD38XmsF2lsLs%3D 12174870 (Pubitemid 34857009)
52. I Opitz B Sigrist S Hillinger, et al. 2007 Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma Lung Cancer. 56 327 336 10.1016/j.lungcan.2007.01.024 1:STN:280:DC%2BD2s3ns12hsQ%3D%3D 17383050 (Pubitemid 46679090)
53. Cotran R, Kumar V, Collins T, Robbins S. Robbins pathologic basis of disease. Philadelphia: WB Saunders; 1999.
54. B Brüne 2003 Nitric oxide: NO apoptosis or turning it ON? Cell Death Differ. 10 864 869 10.1038/sj.cdd.4401261 12867993 (Pubitemid 36939696)
55. H Wajant 2002 The Fas signaling pathway: More than a paradigm Science 296 1635 6 10.1126/science.1071553 1:CAS:528:DC%2BD38XktlChtrk%3D 12040174 (Pubitemid 34579146)
56. R Stendel L Scheurer G Stoltenburg-Didinger M Brook H Möhler 2003 Enhancement of Fas-ligand-mediated programmed cell death by taurolidine Anticancer Res. 23 2309 2314 1:CAS:528:DC%2BD3sXmsFyrt70%3D 12894508 (Pubitemid 36897096)
57. C Braumann M Schoenbeck C Menenakos M Kilian C Jacobi 2005 Effects of increasing doses of a bolus injection and an intravenous long-term therapy of taurolidine on subcutaneous (metastatic) tumor growth in rats Clin Exp Metastasis. 22 77 83 10.1007/s10585-005-4695-4 1:CAS:528:DC%2BD2MXhtFegt77O 16132581 (Pubitemid 41185864)
58. S Susin H Lorenzo N Zamzami, et al. 1999 Molecular characterization of mitochondrial apoptosis-inducing factor Nature. 397 441 446 10.1038/17135 1:CAS:528:DyaK1MXhtFOhu78%3D 9989411 (Pubitemid 29078912)
59. A Takaoka S Hayakawa H Yanai, et al. 2003 Integration of interferon-a/b signalling to p53 responses in tumour suppression and antiviral defence Nature. 424 516 523 10.1038/nature01850 1:CAS:528:DC%2BD3sXlvVGisLw%3D 12872134 (Pubitemid 36975769)
60. Y Crawford N Ferrara 2009 VEGF inhibition: Insights from preclinical and clinical studies Cell Tissue Res. 335 261 269 10.1007/s00441-008-0675-8 1:CAS:528:DC%2BD1cXhsVOru7vP 18766380
61. C Braumann J Tangermann C Jacobi J Mueller W Dubiel 2008 Novel anti-angiogenic compounds for application in tumor therapy-COP9 signalosome-associated kinases as possible targets Mini Rev Med Chem. 8 421 10.2174/138955708784223549 1:CAS:528:DC%2BD1cXkvV2itb8%3D 18473931
62. P Calabresi F Goulette J Darnowski 2001 Taurolidine cytotoxic and mechanistic evaluation of a novel antineoplastic agent 1 AACR. 61 6816 6821 1:CAS:528:DC%2BD3MXntFaisb0%3D (Pubitemid 32896506)
63. E Bobrich C Braumann I Opitz C Menenakos G Kristiansen C Jacobi 2007 Influence of intraperitoneal application of taurolidine/heparin on expression of adhesion molecules and colon cancer in rats undergoing laparoscopy J Surg Res. 137 75 82 10.1016/j.jss.2006.07.013 1:CAS:528:DC%2BD28Xht12ktb7P 17109891 (Pubitemid 44895326)
64. P De Angelis B Fjell K Kravik, et al. 2004 Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil Int J Oncol. 24 1279 1288 15067352
65. T Ota M Maeda S Suto M Tatsuka 2004 LyGDI functions in cancer metastasis by anchoring Rho proteins to the cell membrane Mol Carcinog. 39 206 220 10.1002/mc.20006 1:CAS:528:DC%2BD2cXjt1egur8%3D 15057873 (Pubitemid 38452241)
66. S Duffy J Taylor J Terrell, et al. 2008 Interleukin-6 predicts recurrence and survival among head and neck cancer patients CA Cancer J Clin. 113 750 757 (Pubitemid 351158326)
67. W Liao J Lin C Wu, et al. 2008 Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma Clin Cancer Res. 14 428 10.1158/1078-0432.CCR-07-1032 1:CAS:528:DC%2BD1cXhtVKitb4%3D 18198221 (Pubitemid 351226110)
68. J Heimdal K Kross B Klementsen J Olofsson H Aarstad 2008 Stimulated monocyte IL-6 secretion predicts survival of patients with head and neck squamous cell carcinoma BMC Cancer. 8 34 10.1186/1471-2407-8-34 18234094
69. B Li G Mao C Cao 2007 Effects of inflammatory cytokines on the recurrence of liver cancer after an apparently curative operation J Dig Dis. 8 154 159 10.1111/j.1443-9573.2007.00292.x (Pubitemid 47161789)
70. JL Luo S Maeda LC Hsu H Yagita M Karin 2004 Inhibition of NF- B in cancer cells converts inflammation-induced tumor growth mediated by TNF to TRAIL-mediated tumor regression Cancer Cell. 6 297 305 10.1016/j.ccr.2004.08.012 1:CAS:528:DC%2BD2cXot1KisL8%3D 15380520 (Pubitemid 39222042)
71. J Marx 2004 Cancer research: Inflammation and cancer: The link grows stronger Science 306 966 8 10.1126/science.306.5698.966 1:CAS:528: DC%2BD2cXpsF2ht74%3D 15528423 (Pubitemid 39482883)
72. G Pidgeon J Harmey E Kay M Da Costa H Redmond D Bouchier-Hayes 1999 The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease Br J Cancer. 81 1311 1317 10.1038/sj.bjc.6694369 1:CAS:528:DC%2BD3cXls1Klug%3D%3D 10604727
73. J Harmey C Bucana W Lu, et al. 2002 Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion Int J Cancer. 101 415 422 10.1002/ijc.10632 1:CAS:528:DC%2BD38Xnt1ehsro%3D 12216068
74. L Gong H Greenberg J Perhach S Waldman W Kraft 2007 The pharmacokinetics of taurolidine metabolites in healthy volunteers J Clin Pharmacol. 47 697 10.1177/0091270007299929 1:CAS:528:DC%2BD2sXmvF2jsbg%3D 17395893 (Pubitemid 46800427)
75. C Braumann N Guenther J Pohlenz R Pfirrmann C Menenakos 2009 Wound healing is not impaired in rats undergoing perioperative treatment with the antineoplastic agent taurolidine Eur Surg Res. 42 91 96 10.1159/000182817 1:CAS:528:DC%2BD1MXhslyjsLw%3D 19088475
76. K Plate G Breier H Weich H Mennel W Risau 1994 Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms Int J Cancer. 59 520 529 10.1002/ijc.2910590415 1:STN:280:DyaK2M%2FkvVyrtg%3D%3D 7525492 (Pubitemid 24357278)
77. L Chen L Egan Z Li F Greten M Kagnoff M Karin 2003 The two faces of IKK and NF-B inhibition: Prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion Nat Med. 9 575 81 10.1038/nm849 1:CAS:528:DC%2BD3sXjtlamtL8%3D 12692538 (Pubitemid 36597104)
78. S Rakoff-Nahoum R Medzhitov 2009 Toll-like receptors and cancer Nat Rev Cancer 9 1 57 63 10.1038/nrc2541 1:CAS:528:DC%2BD1cXhsVGlu77P 19052556
79. S Rakoff-Nahoum R Medzhitov 2007 Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88 Science. 317 124 10.1126/science.1140488 1:CAS:528:DC%2BD2sXnt1Sjtb4%3D 17615359 (Pubitemid 47056471)